ImmunoGenesis to Present IND-Enabling Development Progress and Therapeutic Potential of IMGS-203, a Novel STING Agonist, at SITC 2026 Annual Meeting
HOUSTON, Nov. 4, 2026 /PRNewswire/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced upcoming presentations describing the IND-enabling activities and therapeutic potential for IMGS-203, the company's novel Stimulator...
Covered in this story
Call it yourself
No calls on $SITC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Site Centers Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.